Advancing Precision Oncology in Europe with a Globally Validated Liquid Biopsy – Guardant360
Time: 9:40 am
day: Day 1 AM
Details:
- Comprehensive biomarker testing and precision oncology uptake in Europe face adoption challenges due to regulatory, reimbursement and data hurdles
- Guardant Health’s partnerships with leading cancer centers in the EU have accelerated Guardant360 adoption, expanding access to high-quality testing
- Guardant’s successful UK pilot with The Royal Marsden demonstrates how local implementation of Guardant360 drives clinical adoption and improves patient access
